Targeting multidrug-resistant bacteria

July 05, 2012

Genome BC has given SFU microbiology professor Fiona Brinkman and a UBC colleague $413,000 to test a new approach for identifying drugs that work against multidrug-resistant (MDR) bacterial pathogens. “We’re comparing bacterial pathogen proteins with human proteins and identifying small insertions or deletions, called indels, in the bacterial pathogen proteins that we might be able to selectively target to disrupt or de-activate the pathogen protein,” explains Brinkman. “Major pharmaceutical companies haven’t been considering this approach, which represents a novel way to identify new targets for antimicrobial drugs.” She says the proof-of-concept research, co-funded by Indel Therapeutics Inc., will enable the scientists to further test the idea before expanding it further with industry involvement.

No comments yet